1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,683 | 0,686 | 07:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 55,92 | +0,22 % | Novonesis To Acquire Remaining MicroBioGen Shares | CANBERA (dpa-AFX) - Novozymes A/S (NSIS-B.CO), a manufacturer of industrial enzymes, functional proteins, and microorganisms, Monday announced that it has agreed to acquire the remaining shares... ► Artikel lesen | |
| GENMAB | 267,00 | -0,15 % | Genmab A/S Q2 Profit Declines | BRUSSELS (dpa-AFX) - Genmab A/S (GMAB) announced earnings for second quarter that Dropped, from last yearThe company's bottom line totaled $303 million, or $4.91 per share. This compares with... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,980 | -1,73 % | Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? | ||
| MUSTGROW BIOLOGICS | 0,246 | 0,00 % | Bayer, MustGrow Biologics und Nutrien: Wer den Welthunger besiegt, erobert den Agrarmarkt | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Ernährungssicherheit bleibt angespannt durch Konflikte, Klimaextreme und auch knappe Ressourcen. Das setzt die Produktion... ► Artikel lesen | |
| VERICEL | 38,400 | 0,00 % | Vericel Corporation: Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,435 | -2,25 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| FAETH THERAPEUTICS | 30,010 | +0,03 % | Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | - Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement -
- Company changed name to Faeth... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,864 | +7,73 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 8,888 | -3,73 % | REGENXBIO Inc.: REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights | RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027
Long-term surabgene lomparvovec... ► Artikel lesen | |
| AKEBIA | 0,730 | -2,77 % | H.C. Wainwright reiterates Buy on Akebia stock, $6 target | ||
| ZEVRA THERAPEUTICS | 9,840 | 0,00 % | Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041 | ||
| FENNEC PHARMACEUTICALS | 10,900 | +16,58 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | ~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK- Demand Carried into Third Quarter... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 12,645 | 0,00 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results | Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis... ► Artikel lesen | |
| REVANCE THERAPEUTICS | - | - | Revance taps dancer Julianne Hough to choreograph social media push for Botox rival | ||
| CARTESIAN THERAPEUTICS | 7,250 | +0,69 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 Phase 2 TRITON trial of... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,008 (+1,18 %) liegt der Kurs bei 0,684 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.